

### CLAIMS

1. A use of a first agent that attenuates Topoisomerase II (Topo II) activity and a second agent that inhibits Heat Shock Protein 90 (HSP90) activity in the manufacture of a medicament for contemporaneous or sequential administration in chemotherapy.
2. The use according to claim 1 wherein the first agent is a compound selected from:
  - (i) compounds that bind to Topo II and inhibit its activity (e.g. competitive inhibitors or allosteric inhibitors);
  - (ii) compounds which prevent the transcription, translation or expression of Topo II (e.g. ribozymes or antisense DNA molecules);
  - (iii) compounds which inhibit release of Topo II from intracellular stores; and
  - (iv) compounds which increase the rate of degradation of Topo II.
3. The use according to claim 1 or 2 wherein the first agent is a compound that interferes with the breakage and religation of a G segment of DNA.
4. The use according to claim 3 wherein the first agent is a Podophyllotoxin and derivatives and analogues thereof.
5. The use according to claim 4 wherein the first agent is etoposide (VP16) or teniposide.
6. The use according to claim 3 wherein the first agent is an Anthracenedione and derivatives and analogues thereof.
7. The use according to claim 6 wherein the first agent is Mitoxantrone.
8. The use according to claim 3 wherein the first agent is m-AMSA (amsacrine) and derivatives and analogues thereof.

9. The use according to claim 1 or 2 wherein the first agent is a Bisdioxopiperazine and derivatives and analogues thereof.
10. The use according to claim 9 wherein the first agent is ICRF-154, 159, 187 or 193.
11. The use according to claim 1 or 2 wherein the first agent is a thiobarbiturate
12. The use according to claim 11 wherein the first agent is Merbarone or a derivative or analogue thereof.
13. The use according to claim 1 or 2 wherein the first agent is Genistein and derivatives or analogues thereof; or Pyrazoloacridine and derivatives or analogues thereof.
14. The use according to any preceding claim wherein the second agent is a compound selected from:
  - (i) compounds that bind to Hsp90 and inhibit its activity (e.g. competitive inhibitors or allosteric inhibitors);
  - (ii) compounds which prevent the transcription, translation or expression of Hsp90 (e.g. ribozymes or antisense DNA molecules);
  - (iii) compounds which inhibit release of Hsp90 from intracellular stores; and
  - (iv) compounds which increase the rate of degradation of Hsp90.
15. The use according to claim 14 wherein the second agent is Geldanamycin or a derivative or analogue thereof.
16. The use according to claim 15 wherein the second agent is 17-Allylamino, 17-demethoxygeldanamycin (17AAG).
17. The use according to claim 14 wherein the second agent is Radicicol or a derivative or analogue thereof.

18. The use according to any preceding claim wherein the chemotherapy is for cancer treatment.

19. The use according to claim 18 for the treatment of solid tumours.

20. The use according to claim 19 for the treatment of bowel cancer, small cell and non-small cell lung cancer, head and neck cancer, breast cancer, bladder cancer or malignant melanoma.

21. The use according to claim 18 for the treatment of paediatric tumours.

22. The use according to claim 18 or 21 for the treatment of neuroblastoma, leukaemias and lymphomas.

23. The use according to claim 5 wherein the first agent is etoposide and it is used in the treatment of cancers selected from:

Adult Acute Myeloid Leukemia

Adult Hodgkin's Disease

Adult Non-Hodgkin's Lymphoma

AIDS-Related Lymphoma

Carcinoma of Unknown Primary

Childhood Acute Myeloid Leukemia

Childhood Brain Tumor

Childhood Cerebral Astrocytoma

Childhood Ependymoma

Childhood Hodgkin's Disease

Childhood Liver Cancer

Childhood Medulloblastoma

Childhood Non-Hodgkin's Lymphoma

Childhood Rhabdomyosarcoma

Childhood Supratentorial Primitive Neuroectodermal and Pineal Tumors

Childhood Visual Pathway and Hypothalamic Glioma

Endometrial Cancer

Ewing's Family of Tumors Including Primitive Neuroectodermal Tumor (PNET)

Extragenital Germ Cell Tumors

Gastric Cancer

Gastrointestinal Carcinoid Tumor

Gestational Trophoblastic Tumor

Kaposi's Sarcoma

Malignant Thymoma

Neuroblastoma

Non-small Cell Lung Cancer

Osteosarcoma/Malignant Fibrous Histiocytoma of Bone

Ovarian Epithelial Cancer

Ovarian Germ Cell Tumor

Pediatric Extracranial Germ Cell Tumor

Prostate Cancer

Retinoblastoma

Small Cell Lung Cancer

Testicular Cancer

Unusual Cancers of Childhood

Wilms' Tumor and Other Childhood Kidney Tumors

24. The use according to any one of claims 1 - 17 wherein the chemotherapy is for:

antibacterial treatments;

antifungal treatments;

the treatment of AIDS/HIV;

the treatment of multiple sclerosis; or

the killing and inhibition of proliferation of any organism.

25. The use according to any preceding claim wherein the chemotherapy is for prophylactic treatment.

26. A delivery system for use in a gene therapy technique, said delivery system comprising:

- (i) a first DNA molecule encoding for a protein which directly or indirectly attenuates Topoisomerase II activity; and
- (ii) a second DNA molecule encoding for a protein which directly or indirectly inhibits Heat Shock Protein 90 activity;

wherein said DNA molecules are capable of being transcribed to allow the expression of said proteins and thereby be effective for chemotherapy.

27. The use of a delivery system according to claim 16 for the manufacture of a medicament for use in chemotherapy.

28. The use according to claim 27 for the treatment of conditions defined by any one of claims 18 to 25.

29. A method of screening a first and a second compound, to test whether or not said compounds has efficacy for use in combination as a chemotherapy, comprising:

- (a) exposing said compounds to Topoisomerase II and evaluating whether or not said compounds bind thereto;
- (b) exposing said compounds to Heatshock Protein 90 and evaluating whether or not said compounds bind thereto; and
- (c) selecting a first and second compound, wherein at least one compound binds to Topoisomerase II and at least one compound binds to Heatshock Protein 90 for use in combination as a chemotherapy.

30. A method of screening a compound, to test whether or not said compound has efficacy for use in chemotherapy, comprising exposing said compound to Topoisomerase II and Heatshock Protein 90 to evaluate whether or not said compound prevents interaction between Topoisomerase II and Heatshock Protein 90.

31. The method according to claim 29 or 30 wherein the compound is screened using Topoisomerase II and Heatshock Protein 90 as binding partners in an interaction trap and evaluating whether or not said compound modulates binding.
32. The method according to claim 31 wherein the interaction trap is a yeast two-hybrid interaction trap.
33. The method according to claim 32 wherein yeast used in the interact trap are permeable to the tested compounds.
34. A method of screening a compound, to test whether or not said compound is carcinogenic, comprising exposing said compound to Topoisomerase II and Heatshock Protein 90 to evaluate whether or not said compound promotes interaction between Topoisomerase II and Heatshock Protein 90.
35. An *in vitro* method for diagnosing whether or not a subject has, or is likely to develop cancer, comprising:
- (i) detecting the level of activity or expression levels of HSP90 and Topoisomerase II from a sample of cells from said subject; and
  - (ii) comparing the level of activity or expression levels of HSP90 and Topoisomerase II in said sample relative to activity expression levels of HSP90 and Topoisomerase II from a non-cancerous sample.
36. An *in vitro* method for evaluating the suitability of chemotherapeutic treatment for administration to a subject, comprising:
- (i) detecting the level of activity or expression levels of HSP90 and Topoisomerase II from a sample of cells from said subject; and
  - (ii) comparing the level of activity or expression levels of HSP90 and Topoisomerase II in said sample relative to activity expression levels of HSP90 and Topoisomerase II from a non-cancerous sample.

37. An *in vitro* method for monitoring the effectiveness of a chemotherapy for treating a subject, comprising:

- (i) detecting the level of activity or expression levels of HSP90 and Topoisomerase II from a sample of cells from said subject; and
- (ii) comparing the level of activity or expression levels of HSP90 and Topoisomerase II in said sample relative to activity expression levels of HSP90 and Topoisomerase II from a non-cancerous sample.